Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04541381 · ClinicalTrials.gov registry record · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
A NA study of Breast Cancer and Head and Neck Cancer, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 860
- Enrollment target
- 1
- Study location
NCT04541381: Recruiting NA study of Breast Cancer and Head and Neck Cancer, sponsored by University of Chicago.
NCT04541381 is a NA study of Breast Cancer and Head and Neck Cancer that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 860 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04541381, a NA study of Breast Cancer and Head and Neck Cancer, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 860 participants
- Enrollment target
- 1
- Study location
Study Summary
Doctors leading this study hope to find out if giving study participants' genetic information to cancer care providers will help personalize chemotherapy dosing decisions and decrease common chemotherapy side effects. Doctors leading the study will collect genetic information from study participants using pharmacogenomics/genotyping. Pharmacogenomics is the study of how the differences in our genes can affect our unique response to medications. This is a randomized study, which means that participants in this study will be randomly assigned (as if "by flip of a coin") to one of two different groups: a "pharmacogenomics group" or "control group".
Conditions Studied
Interventions
- OTHER Availability of clinical decision support based on pharmacogenomic results.
Study Locations (1)
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2028-03-31 |
| Phase | NA |
What NCT04541381 shows while recruiting
NCT04541381 is an interventional study that assigns participants to a tested intervention. The registered 860 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (69% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Availability of clinical decision support based on pharmacogenomic results. is the first listed.
NCT04541381 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04541381 about?
NCT04541381 is a clinical study titled "The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care". Doctors leading this study hope to find out if giving study participants' genetic information to cancer care providers will help personalize chemotherapy dosing decisions and decrease common chemotherapy side effects. Doctors leading the study will collect genetic information from study participants...
What is the current status of trial NCT04541381?
This trial is currently recruiting. It is a NA study. The enrollment target is 860 participants. The study started on 2022-02-07. Estimated completion is 2028-03-31.
What conditions does trial NCT04541381 study?
This clinical trial studies the following conditions: Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Dihydropyrimidine Dehydrogenase Deficiency, UGT1A1 Gene Mutation.
What interventions are being tested in trial NCT04541381?
The interventions under investigation include: Availability of clinical decision support based on pharmacogenomic results. (OTHER).
Who is sponsoring clinical trial NCT04541381?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04541381 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04541381's enrollment target sits among peer trials
860 140th of 1224 higher than 1,085 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- NCT06541574 · 860 participants · Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
- NCT07410117 · 860 participants · Phase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI